Dimensional Fund Advisors LP boosted its position in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 4.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,182,715 shares of the biopharmaceutical company’s stock after buying an additional 290,531 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.05% of Achillion Pharmaceuticals worth $26,433,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new position in Achillion Pharmaceuticals in the 2nd quarter worth $147,000. BlueMountain Capital Management LLC bought a new position in Achillion Pharmaceuticals in the 2nd quarter worth $159,000. GSA Capital Partners LLP bought a new position in Achillion Pharmaceuticals in the 2nd quarter worth $689,000. Alps Advisors Inc. raised its holdings in Achillion Pharmaceuticals by 22.2% in the 3rd quarter. Alps Advisors Inc. now owns 245,245 shares of the biopharmaceutical company’s stock worth $903,000 after purchasing an additional 44,480 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Achillion Pharmaceuticals by 14.5% in the 2nd quarter. Bank of America Corp DE now owns 416,817 shares of the biopharmaceutical company’s stock worth $1,179,000 after purchasing an additional 52,634 shares in the last quarter. Institutional investors own 77.12% of the company’s stock.
Several research analysts have commented on ACHN shares. BidaskClub lowered shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, October 12th. ValuEngine lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, December 18th. Finally, Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating and three have issued a hold rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $4.17.
NASDAQ:ACHN opened at $2.01 on Wednesday. The stock has a market capitalization of $249.51 million, a PE ratio of -3.24 and a beta of 2.11. Achillion Pharmaceuticals, Inc. has a 1-year low of $1.29 and a 1-year high of $4.34.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.02. As a group, research analysts anticipate that Achillion Pharmaceuticals, Inc. will post -0.52 earnings per share for the current fiscal year.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Featured Story: What impact do institutional investors have on markets?
Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.